CD19 and acute lymphoblastic leukemia: Emerging immunotherapies, including monoclonal antibodies and CAR-T cell therapies, offer promising options for refractory or relapsed cases, such as blinatumomab, which is a bispecific T-cell engager targeting CD19 and has demonstrated efficacy in inducing remission among relapsed Ph-like ALL cases [7,46].